TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07477639: A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis

Sponsor: Tr1X, Inc. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 39 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$6,727,920

Rescue Site Savings

+$4,452,300

Unlock Full NCT07477639 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07477639 Rescue Dossier →